News

Novo Nordisk's Wegovy Sales Surge 85% But Compounded Weight Loss Drugs In US Impacts Annual Outlook
Novo Nordisk Q1 sales missed estimates despite strong growth in Wegovy and Ozempic, prompting a cut to its 2025 guidance amid ...
Fierce Pharma14h
Novo's Wegovy takes a hit from compounders, but company expects faster second-half growth
As Novo Nordisk works through a period of transition in the U.S. GLP-1 drug market, sales from the company's star obesity ...
The Cardiology Advisor11h
Novo Nordisk Partners With Telehealth Platforms to Expand Wegovy Access
Novo Nordisk is collaborating with multiple telehealth organizations in an effort to increase patient access to authentic ...
Novo Nordisk Says FDA Accepted New Drug Application for Wegovy Pill
The Bagsvaerd, Denmark, company said that if the application is approved, Wegovy would become the first oral formulation of a ...
Eli Lilly looks set to steal Novo Nordisk’s weight-loss crown
Eli Lilly is proving that being second but better can also pay. Zepbound, the American firm’s weight-loss jab, was approved ...
Novo Nordisk Stock Jumps After Earnings. Compounding Market’s Growth Took it By Surprise
It became clear over the first quarter that the amount of business that had gone to the compounders was just significantly ...
Top Analyst Reports for Novo Nordisk, Honeywell & American Tower
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Honeywell ...
Wegovy seeks FDA approval for a GLP-1 weight-loss pill
Pharmaceutical company Novo Nordisk is waiting on federal approval to sell its blockbuster GLP-1 weight-loss treatment as a pill.